Axelopran for Advanced Cancer in Patients Receiving Opioids

The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main questions it aims to answer are: * Does axelopran show a signal for efficacy in slowing tumor progression? * Is axelopran safe and tolerable for long-term use in this patient population? * Does axelopran show a signal for efficacy in improving bowel function and quality of life? * Does axelopran show

Trial Details

NCT ID
NCT07354919
Phase
PHASE2
Sponsor
HealthPartners Institute
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • axelopran
Locations (sample)
  • Saint Louis Park, Minnesota, United States|44.9483,-93.34801
  • Saint Paul, Minnesota, United States|44.94441,-93.09327

Key Eligibility Criteria

  • Adults (aged 18 or more at enrollment).
  • Histologically or cytologically proven cancer of the prostate (carcinoma), breast (carcinoma), pancreas (carcinoma), and lung (non-small cell lung …
  • Advanced stage (locally advanced or metastatic) with no definitive plans for curative-intent therapy.
  • A minimum life expectancy of at least 2 months at the time of the screening visit.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →